Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: A multicentre randomised controlled trial

Annals of the Rheumatic Diseases

Volumn 65, Issue 9, 2006, Pages 1147-1153

  Braun, J ^a   Zochling, J ^a   Baraliakos, X ^a   Alten, R ^b   Burmester, G ^c   Grasedyck, K ^d   Brandt, J ^e   Haibel, H ^c   Hammer, M ^f   Krause, A ^g   Mielke, F ^h   Tony, H P ⁱ   Ebner, W ^j   Gomor B ^k   Hermann, J ^l   Zeidler, H ^m   Beck, E ⁿ   Baumgaertner, M ^o   Sieper, J ^c  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b Schlossparkklinik   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Rheumatologische Gemeinschaftspraxis   (Germany)

^f Rheumatology Department   (Germany)

^g Immanuel Hospital   (Germany)

^h Rheumatology   (Germany)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j GENERAL HOSPITAL LINZ   (Austria)

^k Lainz Hospital ^*  (Hungary)

^l MEDICAL UNIVERSITY OF GRAZ   (Austria)

^m LEIBNIZ UNIVERSITY HANNOVER   (Germany)

ⁿ Anfomed GmbH   (Germany)

^o PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ANTIGEN; LEUKOCYTE B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENTHESITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING IMPAIRMENT; HUMAN; INFECTION; INFLAMMATION; IRITIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; MULTICENTER STUDY; NAUSEA; PAIN; PAIN ASSESSMENT; PATHOGENESIS; PHARYNGITIS; PHYSICAL CAPACITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SPINAL PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO; VOMITING;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; BACK PAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; SULFASALAZINE; TREATMENT OUTCOME;

EID: 33747774889     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.052878     Document Type: Article

References (29)

1. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondyloarthropathy Study Group preliminary criteria of the classification of spondyloarthropathy. Arthritis Rheum 1991;34:1218-27.
2. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
3. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988;15:1109-14.
4. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of Spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
5. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9.
6. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005;(2):CD004800.
7. Garrett S, Jenkinson TR, Kennedy LG, Whitelock HC, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis. The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
8. Calin A, Garrett S, Whitelock HC, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis. The Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
9. Stucki G, Meier D, Stucki S, Michel BA, Tyndall AG, Dick W, et al. Evaluation einer deutschen Version des WOMAC (Western Ontario und McMaster Universities) Arthroseindex. Z Rheumatol 1996;55:40-9.
10. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
11. Fricke U, Günther J, Zawinell A. Verwendungsmöglichkeiten des ATC/DDD-Systems. In: Methodik der ATC-Klassifikation und DDD-Festlegung für den deutschen Arzneimittelmarkt. 3rd edn. Bonn: Wissenschaftliches Institut der AOK, 2003:42-50.
12. Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology 2005;44:1483-91.
13. Nissilä M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988;31:1111-16.
14. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14:340-3.
15. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. BMJ 1986;293:911-14.
16. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
17. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis. A systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
18. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the International ASAS consensus statement for me use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
19. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, et al. Successful short-term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004;31:531-8.
20. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short-term treatment of patients with severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002;29:118-22.
21. Calin A, Nakache J-P, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 1999;38:878-82.
22. Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, et al. Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. Z Rheumatol 2003;62:264-73.
23. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewe R, Dougados M, Mielants H, et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum 2004;51:154-9.
24. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
25. Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh Jr PF, et al. The efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005:62:1563-7.
26. Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
27. von der Linden SM, Valkenburg HA, de Jongh B, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241-9.
28. Olivieri I, Salvarani C, Cantini F, Ciancio G, Padula A. Ankylosing spondyloarthritis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol 2001;13:280-4.
29. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis - a reassessment of the clinical history for classification and diagnosis. Arthritis Rheum 2006;54:569-78.